The incidence of Frey syndrome and treatment with botulinum toxin in the Central Denmark Region

OBJECTIVES: Frey syndrome (FS) is a common complication to large salivary glands surgery. This study primarily aims to describe the incidence of FS among parotid surgery patients in the Central Denmark Region. The secondary aim is to describe predisposing characteristics to syndrome development and the effect of treatment with botulinum toxin (Botox) injection. METHODS: This is a retrospective qualitative study spanning the years 2015–2020. Data on patients diagnosed with FS after parotid surgery with symptoms severe enough to require Botox was extracted from electronic patient records. Incidence of FS development was calculated using data from all parotid gland surgeries in the same period and region. RESULTS: The incidence of treatment‐requiring FS was 2.6% (20/775), with an annual incidence ranging from 0.8% (1/125) in 2017 to 4.5% (5/112) in 2016. Difference in FS development for men and women was not statistically significant (p = .07), although it was significantly more common after total parotidectomy compared to superficial resection (p = .003), and after malignant compared to benign diagnosis (p = .01). Complications in the postoperative period arose for 30% of FS patients. Repeated treatment with Botox was necessary after 6–12 months and at a median interval of 11 months. Forty‐five percent of patients received only one injection. The average dose per injection was 48.3 IU. CONCLUSION: This study revealed a rather low incidence of FS in the Central Denmark Region compared to current international literature. Total parotidectomy and malignant diagnosis predisposed to syndrome development. Botox injection had a wide‐ranging effective duration but typically lasted for around 1 year. LEVEL OF EVIDENCE: Level IV.